Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Biohaven Ltd. ( (BHVN) ).
On January 12, 2026, Biohaven Ltd. announced it would deliver an investor presentation outlining progress and plans across its diversified drug development platforms, highlighting its MoDE and TRAP extracellular degrader technologies that leverage hepatic ASGPR to selectively remove disease-causing proteins while preserving the broader immune system. The presentation emphasized upcoming pivotal trial starts in 2026 for BHV-1400 in IgA nephropathy and BHV-1300 in Graves’ disease, showcased BHV-1400’s recognition by the nephrology community and alignment with updated KDIGO 2025 guidelines that prioritize early, Gd-IgA1–targeted intervention, and positioned Biohaven’s degrader portfolio and broader pipeline as a scalable, patient-friendly engine designed to drive near-term clinical catalysts and long-term value for stakeholders in autoimmune and renal disease markets.
The most recent analyst rating on (BHVN) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Biohaven Ltd. stock, see the BHVN Stock Forecast page.
Spark’s Take on BHVN Stock
According to Spark, TipRanks’ AI Analyst, BHVN is a Neutral.
Score is held down primarily by weak financial performance (no revenue, large losses, heavy cash burn, and negative equity with higher debt) and bearish technicals (price below key moving averages with negative MACD). Corporate financing events modestly support the score by improving near-term liquidity, while valuation metrics offer limited support due to negative earnings and no dividend yield provided.
To see Spark’s full report on BHVN stock, click here.
More about Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company focused on developing innovative therapies across oncology, inflammation and immunology, ion channel disorders and neurology. Its pipeline includes antibody-drug conjugates such as Trop2, FGFR3 and CD30 ADCs, protein degraders based on its MoDE and TRAP platforms, a TYK2/JAK1 inhibitor, TRPM3 antagonists, Kv7 ion-channel activators, myostatin/activin-targeting agents and glutamate-modulating programs like troriluzole, with an emphasis on first-in-class or best-in-class treatments for serious autoimmune and neurological diseases.
Average Trading Volume: 4,077,321
Technical Sentiment Signal: Sell
Current Market Cap: $1.65B
For detailed information about BHVN stock, go to TipRanks’ Stock Analysis page.